Osteoblast

DGAP-News: Sirana Pharma enters into a collaborative research agreement with Pfizer to investigate a novel treatment for a rare bone disease

Retrieved on: 
Thursday, June 30, 2022
Lists of diseases, Patient, CEO, Biotechnology, Research, MicroRNA, Muscle weakness, Senior, Osteoblast, Amelogenesis imperfecta, Disease, Mirna, Bone disease, Bone, Pharmaceutical industry, Sarcopenia, Pfizer

June 2022 - Sirana Pharma GmbH, a biotechnology company focusing on the development of innovative and effective treatments for unmet medical needs in muscle and bone diseases, announced today a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease.

Key Points: 
  • June 2022 - Sirana Pharma GmbH, a biotechnology company focusing on the development of innovative and effective treatments for unmet medical needs in muscle and bone diseases, announced today a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concept for a rare bone disease.
  • The collaboration will utilize Siranas proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.
  • We look forward to working together with the Sirana team to further explore this new and innovative investigational approach, utilizing miRNA-targeting for the potential treatment of rare bone diseases.
  • Initially, Sirana focuses on the development of first-in-class molecules to treat Sarcopenia age related muscle weakness - and Osteogenesis imperfecta inherited brittle bone disease (an orphan drug indication).

Cortexyme Announces Agreement to Acquire Novosteo

Retrieved on: 
Tuesday, May 10, 2022
Research, Infectious Diseases, Dental, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Board, Bone, U.S. Securities and Exchange Commission, Investment, Bone fracture, Forward-looking statement, Board of directors, IND, Nasdaq, Twitter, Birth, Osteogenesis imperfecta, Collagen, Director, Safety, Time, Patient, Doctor of Philosophy, Security (finance), Review, Degenerative disease, Wilson Sonsini Goodrich & Rosati, FDA, Periodontal disease, Cooley LLP, Therapy, Genetic code, Leadership, Osteoblast, CMO, Bone disease, SEC, CEO, News, Growth, Acquisition, Pharmaceutical industry, Management, Medical imaging

Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.

Key Points: 
  • Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.
  • We intend to capitalize on the combined assets of Novosteo and Cortexyme by driving our therapeutic candidates through development, expanding our targeted drug discovery platform, and pursuing new business development opportunities.
  • Cooley LLP acted as legal advisor to Cortexyme and Wilson Sonsini Goodrich & Rosati acted as legal advisor to Novosteo.
  • To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Adge Pharmaceuticals partners with Cyan Bio of Korea to advance treatments for rare pediatric diseases in Asian countries

Retrieved on: 
Tuesday, April 26, 2022
People, CEO, Osteoporosis, Amelogenesis imperfecta, Rett syndrome, MECP2, Walking, Lists of diseases, Cyan, Roche, Seizure, Fracture, Safety, Intellectual disability, Mutation, Neurodevelopmental disorder, Osteogenesis imperfecta, Pharmaceutical industry, Osteoblast, Adge Cutler

MOUNTAIN VIEW, Calif., April 25, 2022 /PRNewswire/ -- Adge Pharmaceuticals ("Adge") has entered into a license agreement with Korea-based Cyan Bio, Inc. ("Cyan").

Key Points: 
  • MOUNTAIN VIEW, Calif., April 25, 2022 /PRNewswire/ -- Adge Pharmaceuticals ("Adge") has entered into a license agreement with Korea-based Cyan Bio, Inc. ("Cyan").
  • The territories include Korea, Greater China, Japan, India and Southeast Asian countries.
  • In parallel with the licensing agreement, Cyan will make an equity investment in Adge.
  • "Cyan Bio ( www.cyanbio.com ) is a Korea basedcompanyfocused on identifying and nurturing promising opportunities that address unmet medical needs.

Nanovis' Best-In-Class Nanotechnology Enables Record Sales Growth

Retrieved on: 
Tuesday, April 19, 2022
Patent, Technology, Research, Element, Science, Infection, Nano, Hip, Trauma, CITY, Patient, Spine, Interbody fusion cage, Growth, Minimally invasive procedure, Knee, Stem cell, Global Health, Federation of Internet Solution Providers of the Americas, Skin, Solution, Osteoblast, Nanotechnology, HA, Physician, Titanium, FDA, Industry, Pharmaceutical industry, Medical device, Antibiotics, Elective surgery

COLUMBIA CITY, Ind., April 19, 2022 /PRNewswire-PRWeb/ -- Nanovis, a technology-driven company committed to discovering unmet clinical needs, developing innovative and enabling solutions, and validating new technologies for clinical and market acceptance, announces subsidiary, Nanovis Spine, achieved record sales for FY 2021, driven by their best-in-class nanotechnology portfolio of interbodies and pedicle screws. The company's revenue growth has remained strong in 2022 with Q1 performance of 37% over the same period in 2021, the largest period growth in company history.

Key Points: 
  • The company's revenue growth has remained strong in 2022 with Q1 performance of 37% over the same period in 2021, the largest period growth in company history.
  • Regulatory Validation: demonstrated the elements to be considered nanotechnology as outlined in the FDA nanotechnology guidance document, on both commercially pure titanium and titanium alloy.
  • "Nanotechnology enables growth.
  • Founded in 2008, Nanovis has become the market leader in nanotechnology used to improve the biological response of orthopedic implants.

Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma

Retrieved on: 
Wednesday, March 30, 2022
Method, Florida Atlantic University, Research institute, Atlantic University, Plasma, Therapy, Bone destruction patterns in periodontal disease, H. Lee Moffitt Cancer Center & Research Institute, Osteoclast, Lymphatic system, Bone marrow, Multiple myeloma, Antibody, Cancer, Osteoblast, CEO, B-cell lymphoma, Solubility, Quality of life, LLC, B cell, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Patient, Disease, Partnership, Pharmaceutical industry

"We are delighted to work with Sterotherapeutics to further develop this novel line of highly selective MMP-13 inhibitors for the treatment of multiple myeloma.

Key Points: 
  • "We are delighted to work with Sterotherapeutics to further develop this novel line of highly selective MMP-13 inhibitors for the treatment of multiple myeloma.
  • Multiple myeloma is a treatable, but incurable cancer of the bone marrow plasma cells.
  • SteroTherapeutics lead products have been proven in previous animal and human studies to possess a strong safety profile and established mechanisms of action.
  • In each individual disease target Sterotherapeutics embraces the opportunity to provide safe, effective treatments and restore an optimal quality of life.

Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website

Retrieved on: 
Wednesday, December 15, 2021
Therapy, Teaching hospital, VU University Medical Center, Lymphatic system, MDS, Laquinimod, Myelodysplastic syndrome, Osteoblast, NASDAQ, 2021 Essex County Council election, Bone marrow suppression, CEO, Biotechnology, CET, Patient, Disease, CFO, Multiple myeloma, Vrije Universiteit Amsterdam, ASH, Brussels, Partnership, Active, EST, Naptumomab estafenatox, ACTI, Pharmaceutical industry, Medical device, Vitro

Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the companys website.

Key Points: 
  • Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the companys website.
  • The data were presented at two poster presentations at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia.
  • The results presented are part of Active Biotechs program to address the unmet medical needs to treat hematological malignances, including multiple myeloma.
  • The first poster is from our collaboration with an academic group at Vrije Universiteit, Brussel, to further study tasquinimod in the preclinical setting of multiple myeloma.

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Retrieved on: 
Thursday, November 4, 2021
Teaching hospital, Naptumomab estafenatox, CFO, 2021 Essex County Council election, Biotechnology, Active, III, MDS, Abstract (summary), Bone marrow suppression, Partnership, Patient, CET, NASDAQ, ACTI, Laquinimod, Multiple myeloma, ASH, Central European, Lymphatic system, VU University Medical Center, CEO, EU, Therapy, Osteoblast, Animal, Pharmaceutical industry, Medical device

Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.

Key Points: 
  • Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.
  • Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro Poster session 636.
  • Myelodysplastic Syndromes Basic and Translational: Poster II., Dec 12, 2021, 6.00-8.00 p.m. M. Wobus et al., University Hospital Dresden, Germany.
  • Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor's ability to grow and metastasize.

Elite HRT Publishes Information on Zomacton

Retrieved on: 
Monday, October 11, 2021
Biotechnology, Other Consumer, Consumer, Health, Pharmaceutical, Growth hormone, History, Telehealth, Allergy, Hormone, Health status of Asian Americans, Osteoclast, Physician, Diabetes, Growth, Regulatory affairs, Education, Health, Osteoblast, Weight loss, Scoliosis, Pregnancy, TRT, Solution, Growth hormone therapy, HGH, Patient, Mellitus, Calcium, HRT, Pharmaceutical industry

Elite HRT is happy to have this online resource published freely for those considering Zomacton and seeking information on the medication.

Key Points: 
  • Elite HRT is happy to have this online resource published freely for those considering Zomacton and seeking information on the medication.
  • About Elite HRT: Elite HRT is a telemedicine firm led by a network of physicians specializing in hormone replacement therapies.
  • With unique approaches to HRT, TRT, HGH, and more, Elite HRT works to tailor solutions uniquely created for specific patients, all at affordable rates.
  • Those wanting to learn more and contact Elite HRT can visit https://www.elitehrt.com/ and submit a contact request form with background information today.

Nexxt Spine Announces Commercial Launch of the NEXXT MATRIXX® Stand-Alone Cervical System

Retrieved on: 
Wednesday, September 29, 2021
Engineering, Health, Medical Devices, Surgery, Manufacturing, Other Health, Other Manufacturing, Elasticity, Trauma, Titanium, ACDF, Osteoblast, Multimedia, Patient, Disease, LLC, Center, 3D, Operation Time, Technology, National Center for Spinal Disorders, PEEK, Lordosis, Safety, Industry, Medical device

Nexxt Spine, LLC , an industry leader in the surgical treatment of spinal disorders, announces the commercial launch of the NEXXT MATRIXX Cervical Stand-Alone System.

Key Points: 
  • Nexxt Spine, LLC , an industry leader in the surgical treatment of spinal disorders, announces the commercial launch of the NEXXT MATRIXX Cervical Stand-Alone System.
  • The NEXXT MATRIXX Cervical Stand-Alone System provides the strength and biocompatibility of titanium and a modulus of elasticity comparable to PEEK.
  • We are excited to deliver this unique cervical system and the NEXXT MATRIXX technology to our customers said Andy Elsbury, President of Nexxt Spine.
  • For more information on the NEXXT MATRIXX Cervical Stand-Alone System, visit http://www.NexxtSpine.com/ or email [email protected] .

Camber Spine Launches SPIRA-P and SPIRA-T Implants for National Distribution

Retrieved on: 
Wednesday, September 22, 2021
Health, FDA, Medical Devices, Hospitals, Surgery, Other Health, General Health, Porosity, Food, DDD, NASS, Camber, North American Spine Society, Degenerative disc disease, Osteoblast, Subsidence, News, FDA, Patient, Annual general meeting, Cell adhesion, CEO, Food and Drug Administration, PLIF, Risk, 3D, Technology, Anatomy, Lordosis, Spine, MIS, Bookbinding, 3D printing, Antibiotics, Baking

Camber Spine , a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.

Key Points: 
  • Camber Spine , a leading innovator in spine and medical technologies, has initiated the full national launch of its SPIRA-P Posterior Lumbar Spacer and SPIRA-T Oblique Posterior Lumbar Spacer devices.
  • Plus, its uniquely designed surface allows for cell adhesion and bone cell proliferation while its interconnected porosity design mimics bone.
  • Innovative spine and medical technology company Camber Spine Technologies is dedicated to creating surgeon-designed solutions in MIS and minimally disruptive access for the treatment of complex spinal pathology.
  • Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, Camber Spine is making quantum leaps in the spinal fusion market.